Effect of Gestational Age at Tenofovir-Emtricitabine-Efavirenz Initiation on Adverse Birth Outcomes in Botswana

• DOI: 10.1093/jpids/piy006
• Publication Date: 2018-01-17T19:17:34Z
• Authors: Rebecca Zash; Kathryn Rough; Denise L Jacobson; Modiegi Diseko; Gloria Mayondi; Mompati Mmalane; Max Essex; Chipo Petlo; Shahin Lockman; Joseph Makhema; Roger L Shapiro
• Keywords: Emtricitabine; Efavirenz; Regimen; Tenofovir

Among human immunodeficiency virus-positive women in Botswana on the recommended first-line antiretroviral therapy regimen, tenofovir-emtricitabine-efavirenz, initiated within first or early second trimester, we found no increased risk of stillbirth, neonatal death, preterm/very preterm delivery, infant being born small very for gestational age. Treatment with tenofovir-emtricitabine-efavirenz <1 year before conception delivery slightly over late-second-trimester treatment initiation (adjusted ratio, 1.33 [95% confidence interval, 1.04-1.70]).